EUVIMEDEUVIMED entdecken
Open Access

Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India

Dharna Gupta iD, Nidhi Gupta iD, Navneet Singh iD, Shankar Prinja iD

JCO Global Oncology · 2024-02 · (10)

DOI: 10.1200/go.23.00260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024-02. Verfasst von Dharna Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pyrimidines, Sulfones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Targeted therapies, such as crizotinib and ceritinib, have shown promising results in treating non–small cell lung cancer (NSCLC) with specific oncogenic drivers like anaplastic lymphoma kinase ( ALK), c-ros ( ROS1) oncogene, etc. This study aims to assess the cost-effectiveness of these therapies for patients with NSCLC in India. METHODS The Markov model consisted of three health states: progression-free survival, progressive disease, and death. Lifetime costs and consequences were estimated for three treatment arms: crizotinib, ceritinib, and chemotherapy for patients with ALK- and ROS1-positive NSCLC. Incremental cost per quality-adjusted life-year (QALY) gained with crizotinib and ceritinib was compared to chemotherapy and assessed using a willingness-to-pay threshold of one-time per capita gross domestic product in India. RESULTS The total lifetime cost per patient for ALK-positive NSCLC was ₹332,456 ($4,054 US dollars [USD]), ₹1,284,100 ($15,659 USD), and ₹2,337,779 ($28,509 USD) in the chemotherapy, crizotinib, and ceritinib arms, respectively. The mean QALYs lived per patient were 1.20, 2.21, and 3.34, respectively. For patients with ROS1-positive NSCLC, the total cost was ₹323,011 ($3,939 USD) and ₹1,763,541 ($21,507 USD) for chemotherapy and crizotinib, with mean QALYs lived per patient of 1.16 and 2.73, respectively. Nearly 92% and 81% reduction in the price of ceritinib and crizotinib is required to make it a cost-effective treatment option for ALK- and ROS1-positive NSCLC, respectively. CONCLUSION Our study findings suggest that the prices of ceritinib and crizotinib need to be reduced significantly to justify their value for inclusion in India's publicly financed health insurance scheme for treatment of patients with locally advanced/metastatic ALK- and ROS1-positive NSCLC, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPyrimidinesSulfonesHumansAnaplastic Lymphoma KinaseCrizotinibCost-Benefit AnalysisProtein-Tyrosine KinasesProto-Oncogene Proteins

Substanzen

Anaplastic Lymphoma KinaseceritinibCrizotinibProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, humanPyrimidinesSulfones

Autor:innen und Institutionen

  • Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India.
  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

ORCID-Profile: Dharna Gupta, Nidhi Gupta, Navneet Singh, Shankar Prinja

Zitieren

APA

Gupta, D., Gupta, N., Singh, N., & Prinja, S. (2024). Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India. JCO Global Oncology. https://doi.org/10.1200/go.23.00260

Vancouver

Gupta D, Gupta N, Singh N, Prinja S. Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India. JCO Global Oncology. 2024. doi:10.1200/go.23.00260

BibTeX
@article{Gupta2024,
  author = {Gupta, Dharna and Gupta, Nidhi and Singh, Navneet and Prinja, Shankar},
  title = {Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India},
  journal = {JCO Global Oncology},
  year = {2024},
  number = {10},
  doi = {10.1200/go.23.00260}
}
Kostenlos starten →